BioSpace News Archive

Galmed announces positive late-stage results in biopsy-proven NASH patients.

A letter published Wednesday in the NEJM links a stroke patient’s death to lecanemab. Eisai investigators respond.

BioSpace’s exclusive Hotbed Maps highlights nine different regions to watch across the U.S. The maps, made in vibrant color for BioSpace showcases a one-of-a-kind glance at some of 2023’s headline-making companies.

Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.

NovoCure’s novel cancer-fighting platform hits the mark in non-small cell lung cancer.

Vyluma, Inc. announced it will present at the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12, 2023 in San Francisco, Calif.

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, announced that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration to discuss advancing IMC-1 into Phase 3 development as a treatment for FM has been scheduled for mid-March 2023.

Chimerix announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer.

Landos Biopharma, Inc. announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30,909,090 shares of its common stock at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors LLC, Landos’ largest stockholder.